Use of mesenchymal stem cells to treat liver fibrosis: Current situation and future prospects

World Journal of Gastroenterology

Volumn 21, Issue 3, 2015, Pages 742-758

  Berardis, Silvia ^a   Sattwika, Prenali Dwisthi ^a   Najimi, Mustapha ^a   Sokal, Etienne Marc ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

Cell therapy; Cirrhosis; Hepatic stellate cells; Liver fibrosis; Mesenchymal stem cells

Indexed keywords

ALPHA TOCOPHEROL; ANGIOPOIETIN 1; ANTIOXIDANT; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; COLCHICINE; CONNECTIVE TISSUE GROWTH FACTOR; ENDOCANNABINOID; ENDOTHELIN RECEPTOR ANTAGONIST; GAMMA INTERFERON; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 4; INTERLEUKIN 6; LEPTIN; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PLATELET DERIVED GROWTH FACTOR; RIBAVIRIN; SMALL INTERFERING RNA; THYROID HORMONE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNINDEXED DRUG; URSODEOXYCHOLIC ACID; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN;

APOPTOSIS; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CARBON TETRACHLORIDE-INDUCED LIVER FIBROSIS; CD4+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL HOMING; CELL PROLIFERATION; CLINICAL TRIAL (TOPIC); COLLAGEN DEGRADATION; CORD BLOOD STEM CELL TRANSPLANTATION; EMBRYONIC STEM CELL; ENGRAFTMENT; EXTRACELLULAR MATRIX; FIBROGENESIS; HEPATITIS; HEPATITIS B; HEPATITIS C; HEPATOCYTE TRANSPLANTATION; HISTOLOGY; HUMAN; IMMUNOMODULATION; IN VITRO STUDY; LIVER FIBROSIS; LIVER FUNCTION; LIVER PARENCHYMA; LIVER REGENERATION; LIVER SINUSOID; MESENCHYMAL STEM CELL; MESENCHYMAL STEM CELL TRANSPLANTATION; MODEL FOR END STAGE LIVER DISEASE SCORE; MYOFIBROBLAST; NATURAL KILLER CELL; NONALCOHOLIC FATTY LIVER; NONHUMAN; OUTCOME ASSESSMENT; PARACRINE SIGNALING; PATHOPHYSIOLOGY; PLURIPOTENT STEM CELL; REGENERATIVE MEDICINE; REGULATORY T LYMPHOCYTE; REVIEW; STELLATE CELL; ANIMAL; CELL SURVIVAL; GRAFT SURVIVAL; LIVER; LIVER CIRRHOSIS; MESENCHYMAL STROMA CELL; METABOLISM; PATHOLOGY; PROCEDURES; TREATMENT OUTCOME;

ANIMALS; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; GRAFT SURVIVAL; HUMANS; LIVER; LIVER CIRRHOSIS; LIVER REGENERATION; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; REGENERATIVE MEDICINE; TREATMENT OUTCOME;

EID: 84921451500     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v21.i3.742     Document Type: Review

References (161)

1. Friedman SL. Liver fibrosis - from bench to bedside. J Hepatol 2003; 38 Suppl 1: S38-S53 [PMID: 12591185 DOI: 10.1016/S0168-8278(02)00429-4].
2. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Abraham J, Adair T, Aggarwal R, Ahn SY, Alvarado M, Anderson HR, Anderson LM, Andrews KG, Atkinson C, Baddour LM, Barker-Collo S, Bartels DH, Bell ML, Benjamin EJ, Bennett D, Bhalla K, Bikbov B, Bin Abdulhak A, Birbeck G, Blyth F, Bolliger I, Boufous S, Bucello C, Burch M, Burney P, Carapetis J, Chen H, Chou D, Chugh SS, Coffeng LE, Colan SD, Colquhoun S, Colson KE, Condon J, Connor MD, Cooper LT, Corriere M, Cortinovis M, de Vaccaro KC, Couser W, Cowie BC, Criqui MH, Cross M, Dabhadkar KC, Dahodwala N, De Leo D, Degenhardt L, Delossantos A, Denenberg J, Des Jarlais DC, Dharmaratne SD, Dorsey ER, Driscoll T, Duber H, Ebel B, Erwin PJ, Espindola P, Ezzati M, Feigin V, Flaxman AD, Forouzanfar MH, Fowkes FG, Franklin R, Fransen M, Freeman MK, Gabriel SE, Gakidou E, Gaspari F, Gillum RF, Gonzalez-Medina D, Halasa YA, Haring D, Harrison JE, Havmoeller R, Hay RJ, Hoen B, Hotez PJ, Hoy D, Jacobsen KH, James SL, Jasrasaria R, Jayaraman S, Johns N, Karthikeyan G, Kassebaum N, Keren A, Khoo JP, Knowlton LM, Kobusingye O, Koranteng A, Krishnamurthi R, Lipnick M, Lipshultz SE, Ohno SL, . Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2095-2128 [PMID: 23245604 DOI: 10.1016/S0140-6736(12)61728-0].
3. Zatonski WA, Sulkowska U, Manczuk M, Rehm J, Boffetta P, Lowenfels AB, La Vecchia C. Liver cirrhosis mortality in Europe, with special attention to Central and Eastern Europe. Eur Addict Res 2010; 16: 193-201 [PMID: 20606444 DOI: 10.1159/000317248].
4. Bosch J, García-Pagán JC. Complications of cirrhosis. I. Portal hypertension. J Hepatol 2000; 32: 141-156 [PMID: 10728801 DOI: 10.1016/S0168-8278(00)80422-5].
5. Quigley EM. Gastrointestinal dysfunction in liver disease and portal hypertension Gut-liver interactions revisited. Dig Dis Sci 1996; 41: 557-561 [PMID: 8617136 DOI: 10.1007/BF02282341].
6. Cárdenas A. Hepatorenal syndrome: a dreaded complication of end-stage liver disease. Am J Gastroenterol 2005; 100: 460-467 [PMID: 15667508 DOI: 10.1111/j.1572-0241.2005.40952.x].
7. Wong F, Girgrah N, Graba J, Allidina Y, Liu P, Blendis L. The cardiac response to exercise in cirrhosis. Gut 2001; 49: 268-275 [PMID: 11454805 DOI: 10.1136/gut.49.2.268].
8. Huffmyer JL, Nemergut EC. Respiratory dysfunction and pulmonary disease in cirrhosis and other hepatic disorders. Respir Care 2007; 52: 1030-1036 [PMID: 17650360].
9. Collier J. Bone disorders in chronic liver disease. Hepatology 2007; 46: 1271-1278 [PMID: 17886334 DOI: 10.1002/hep.21852].
10. de Franchis R, Dell'Era A. Non-invasive diagnosis of cirrhosis and the natural history of its complications. Best Pract Res Clin Gastroenterol 2007; 21: 3-18 [PMID: 17223493 DOI: 10.1016/j.bpg.2006.07.001].
11. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005; 115: 209-218 [PMID: 15690074 DOI: 10.1172/JCI24282].
12. Pinzani M. Liver fibrosis. Springer Semin Immunopathol 1999; 21: 475-490 [PMID: 10945037 DOI: 10.1007/BF00870306].
13. Anthony PP, Ishak KG, Nayak NC, Poulsen HE, Scheuer PJ, Sobin LH. The morphology of cirrhosis. Recommendations on definition, nomenclature, and classification by a working group sponsored by the World Health Organization. J Clin Pathol 1978; 31: 395-414 [PMID: 649765 DOI: 10.1136/jcp.31.5.395].
14. Friedman SL. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev 2008; 88: 125-172 [PMID: 18195085 DOI: 10.1152/physrev.00013.2007].
15. Knittel T, Dinter C, Kobold D, Neubauer K, Mehde M, Eichhorst S, Ramadori G. Expression and regulation of cell adhesion molecules by hepatic stellate cells (HSC) of rat liver: involvement of HSC in recruitment of inflammatory cells during hepatic tissue repair. Am J Pathol 1999; 154: 153-167 [PMID: 9916930 DOI: 10.1016/S0002-9440(10)65262-5].
16. Sancho-Bru P, Bataller R, Gasull X, Colmenero J, Khurdayan V, Gual A, Nicolás JM, Arroyo V, Ginès P. Genomic and functional characterization of stellate cells isolated from human cirrhotic livers. J Hepatol 2005; 43: 272-282 [PMID: 15964095 DOI: 10.1016/j.jhep.2005.02.035].
17. Takeji M, Moriyama T, Oseto S, Kawada N, Hori M, Imai E, Miwa T. Smooth muscle alpha-actin deficiency in myofibroblasts leads to enhanced renal tissue fibrosis. J Biol Chem 2006; 281: 40193-40200 [PMID: 17090535 DOI: 10.1074/jbc.M602182200].
18. Wells RG, Kruglov E, Dranoff JA. Autocrine release of TGF-beta by portal fibroblasts regulates cell growth. FEBS Lett 2004; 559: 107-110 [PMID: 14960316 DOI: 10.1016/S0014-5793(04)00037-7].
19. Forbes SJ, Russo FP, Rey V, Burra P, Rugge M, Wright NA, Alison MR. A significant proportion of myofibroblasts are of bone marrow origin in human liver fibrosis. Gastroenterology 2004; 126: 955-963 [PMID: 15057733 DOI: 10.1053/j.gastro.2004.02.025].
20. Kalluri R, Neilson EG. Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest 2003; 112: 1776-1784 [PMID: 14679171 DOI: 10.1172/JCI200320530].
21. Meindl-Beinker NM, Dooley S. Transforming growth factorbeta and hepatocyte transdifferentiation in liver fibrogenesis. J Gastroenterol Hepatol 2008; 23 Suppl 1: S122-S127 [PMID: 18336655 DOI: 10.1111/j.1440-1746.2007.05297.x].
22. Schuppan D, Kim YO. Evolving therapies for liver fibrosis. J Clin Invest 2013; 123: 1887-1901 [PMID: 23635787 DOI: 10.1172/JCI66028].
23. Thabut D, Shah V. Intrahepatic angiogenesis and sinusoidal remodeling in chronic liver disease: new targets for the treatment of portal hypertension? J Hepatol 2010; 53: 976-980 [PMID: 20800926 DOI: 10.1016/j.jhep.2010.07.004].
24. Lee CG, Homer RJ, Zhu Z, Lanone S, Wang X, Koteliansky V, Shipley JM, Gotwals P, Noble P, Chen Q, Senior RM, Elias JA. Interleukin-13 induces tissue fibrosis by selectively stimulating and activating transforming growth factor beta(1). J Exp Med 2001; 194: 809-821 [PMID: 11560996 DOI: 10.1084/jem.194.6.809].
25. Meng F, Wang K, Aoyama T, Grivennikov SI, Paik Y, Scholten D, Cong M, Iwaisako K, Liu X, Zhang M, Osterreicher CH, Stickel F, Ley K, Brenner DA, Kisseleva T. Interleukin-17 signaling in inflammatory, Kupffer cells, and hepatic stellate cells exacerbates liver fibrosis in mice. Gastroenterology 2012; 143: 765-776. [PMID: 22687286 DOI: 10.1053/j.gastro.2012.05.049].
26. Gao B, Radaeva S. Natural killer and natural killer T cells in liver fibrosis. Biochim Biophys Acta 2013; 1832: 1061-1069 [PMID: 23022478 DOI: 10.1016/j.bbadis.2012.09.008].
27. Marra F, Aleffi S, Galastri S, Provenzano A. Mononuclear cells in liver fibrosis. Semin Immunopathol 2009; 31: 345-358 [PMID: 19533130 DOI: 10.1007/s00281-009-0169-0].
28. Kelly JD, Haldeman BA, Grant FJ, Murray MJ, Seifert RA, Bowen-Pope DF, Cooper JA, Kazlauskas A. Platelet-derived growth factor (PDGF) stimulates PDGF receptor subunit dimerization and intersubunit trans-phosphorylation. J Biol Chem 1991; 266: 8987-8992 [PMID: 1709159].
29. Wong L, Yamasaki G, Johnson RJ, Friedman SL. Induction of beta-platelet-derived growth factor receptor in rat hepatic lipocytes during cellular activation in vivo and in culture. J Clin Invest 1994; 94: 1563-1569 [PMID: 7929832 DOI: 10.1172/JCI117497].
30. Lee UE, Friedman SL. Mechanisms of hepatic fibrogenesis. Best Pract Res Clin Gastroenterol 2011; 25: 195-206 [PMID: 21497738 DOI: 10.1016/j.bpg.2011.02.005].
31. Inagaki Y, Okazaki I. Emerging insights into Transforming growth factor beta Smad signal in hepatic fibrogenesis. Gut 2007; 56: 284-292 [PMID: 17303605 DOI: 10.1136/gut.2005.088690].
32. Zhou Y, Jia X, Wang G, Wang X, Liu J. PI-3 K/AKT and ERK signaling pathways mediate leptin-induced inhibition of PPARgamma gene expression in primary rat hepatic stellate cells. Mol Cell Biochem 2009; 325: 131-139 [PMID: 19191008 DOI: 10.1007/s11010-009-0027-3].
33. Hellerbrand SC, Tsukamoto H, Brenner DA, Rippe RA. Expression of intracellular adhesion molecule 1 by activated hepatic stellate cells. Hepatology 1996; 24: 670-676 [PMID: 8781341 DOI: 10.1002/hep.510240333].
34. Watanabe A, Hashmi A, Gomes DA, Town T, Badou A, Flavell RA, Mehal WZ. Apoptotic hepatocyte DNA inhibits hepatic stellate cell chemotaxis via toll-like receptor 9. Hepatology 2007; 46: 1509-1518 [PMID: 17705260 DOI: 10.1002/hep.21867].
35. Cohen-Naftaly M, Friedman SL. Current status of novel antifibrotic therapies in patients with chronic liver disease. Therap Adv Gastroenterol 2011; 4: 391-417 [PMID: 22043231 DOI: 10.1177/1756283X11413002].
36. Chang TT, Liaw YF, Wu SS, Schiff E, Han KH, Lai CL, Safadi R, Lee SS, Halota W, Goodman Z, Chi YC, Zhang H, Hindes R, Iloeje U, Beebe S, Kreter B. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 2010; 52: 886-893 [PMID: 20683932 DOI: 10.1002/hep.23785].
37. Marcellin P, Gane E, Buti M, Afdhal N, Sievert W, Jacobson IM, Washington MK, Germanidis G, Flaherty JF, Schall RA, Bornstein JD, Kitrinos KM, Subramanian GM, McHutchison JG, Heathcote EJ. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 2013; 381: 468-475 [PMID: 23234725 DOI: 10.1016/S0140-6736(12)61425-1].
38. Vukobrat-Bijedic Z, Husic-Selimovic A, Mehinovic L, Mehmedovic A, Junuzovic D, Bjelogrlic I, Sofic A, Djurovic A. Analysis of effect of antiviral therapy on regression of liver fibrosis in patient with HCV infection. Mater Sociomed 2014; 26: 172-176 [PMID: 25126010 DOI: 10.5455/msm.2014.26.172-176].
39. Mormone E, George J, Nieto N. Molecular pathogenesis of hepatic fibrosis and current therapeutic approaches. Chem Biol Interact 2011; 193: 225-231 [PMID: 21803030 DOI: 10.1016/j.cbi.2011.07.001].
40. Li JT, Liao ZX, Ping J, Xu D, Wang H. Molecular mechanism of hepatic stellate cell activation and antifibrotic therapeutic strategies. J Gastroenterol 2008; 43: 419-428 [PMID: 18600385 DOI: 10.1007/s00535-008-2180-y].
41. Albanis E, Friedman SL. Antifibrotic agents for liver disease. Am J Transplant 2006; 6: 12-19 [PMID: 16433751 DOI: 10.1111/j.1600-6143.2005.01143.x].
42. Rockey DC. Current and future anti-fibrotic therapies for chronic liver disease. Clin Liver Dis 2008; 12: 939-962, xi [PMID: 18984475 DOI: 10.1016/j.cld.2008.07.011].
43. Ismail MH, Pinzani M. Reversal of hepatic fibrosis: pathophysiological basis of antifibrotic therapies. Hepat Med 2011; 3: 69-80 [PMID: 24367223 DOI: 10.2147/HMER.S9051].
44. Yuan GJ, Zhang ML, Gong ZJ. Effects of PPARg agonist pioglitazone on rat hepatic fibrosis. World J Gastroenterol 2004; 10: 1047-1051 [PMID: 15052691].
45. Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, Balas B, Gastaldelli A, Tio F, Pulcini J, Berria R, Ma JZ, Dwivedi S, Havranek R, Fincke C, DeFronzo R, Bannayan GA, Schenker S, Cusi K. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006; 355: 2297-2307 [PMID: 17135584 DOI: 10.1056/NEJMoa060326].
46. Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, Neuschwander-Tetri BA, Lavine JE, Tonascia J, Unalp A, Van Natta M, Clark J, Brunt EM, Kleiner DE, Hoofnagle JH, Robuck PR. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010; 362: 1675-1685 [PMID: 20427778 DOI: 10.1056/NEJMoa0907929].
47. Rockey DC, Chung JJ. Interferon gamma inhibits lipocyte activation and extracellular matrix mRNA expression during experimental liver injury: implications for treatment of hepatic fibrosis. J Investig Med 1994; 42: 660-670 [PMID: 8521029].
48. Weng HL, Wang BE, Jia JD, Wu WF, Xian JZ, Mertens PR, Cai WM, Dooley S. Effect of interferon-gamma on hepatic fibrosis in chronic hepatitis B virus infection: a randomized controlled study. Clin Gastroenterol Hepatol 2005; 3: 819-828 [PMID: 16234012 DOI: 10.1016/S1542-3565(05)00404-0].
49. Pockros PJ, Jeffers L, Afdhal N, Goodman ZD, Nelson D, Gish RG, Reddy KR, Reindollar R, Rodriguez-Torres M, Sullivan S, Blatt LM, Faris-Young S. Final results of a doubleblind, placebo-controlled trial of the antifibrotic efficacy of interferon-gamma1b in chronic hepatitis C patients with advanced fibrosis or cirrhosis. Hepatology 2007; 45: 569-578 [PMID: 17326152 DOI: 10.1002/hep.21561].
50. Naziroglu M, Cay M, Ustündag B, Aksakal M, Yekeler H. Protective effects of vitamin E on carbon tetrachlorideinduced liver damage in rats. Cell Biochem Funct 1999; 17: 253-259 [PMID: 10587612].
51. Mezey E, Potter JJ, Rennie-Tankersley L, Caballeria J, Pares A. A randomized placebo controlled trial of vitamin E for alcoholic hepatitis. J Hepatol 2004; 40: 40-46 [PMID: 14672612 DOI: 10.1016/S0168-8278(03)00476-8].
52. Nakamura T, Sakata R, Ueno T, Sata M, Ueno H. Inhibition of transforming growth factor beta prevents progression of liver fibrosis and enhances hepatocyte regeneration in dimethylnitrosamine-treated rats. Hepatology 2000; 32: 247-255 [PMID: 10915731 DOI: 10.1053/jhep.2000.9109].
53. Cho JJ, Hocher B, Herbst H, Jia JD, Ruehl M, Hahn EG, Riecken EO, Schuppan D. An oral endothelin-A receptor antagonist blocks collagen synthesis and deposition in advanced rat liver fibrosis. Gastroenterology 2000; 118: 1169-1178 [PMID: 10833492 DOI: 10.1016/S0016-5085(00)70370-2].
54. Hirose A, Ono M, Saibara T, Nozaki Y, Masuda K, Yoshioka A, Takahashi M, Akisawa N, Iwasaki S, Oben JA, Onishi S. Angiotensin II type 1 receptor blocker inhibits fibrosis in rat nonalcoholic steatohepatitis. Hepatology 2007; 45: 1375-1381 [PMID: 17518368 DOI: 10.1002/hep.21638].
55. Abu Dayyeh BK, Yang M, Dienstag JL, Chung RT. The effects of angiotensin blocking agents on the progression of liver fibrosis in the HALT-C Trial cohort. Dig Dis Sci 2011; 56: 564-568 [PMID: 21136163 DOI: 10.1007/s10620-010-1507-8].
56. Rodríguez L, Cerbón-Ambriz J, Muñoz ML. Effects of colchicine and colchiceine in a biochemical model of liver injury and fibrosis. Arch Med Res 1998; 29: 109-116 [PMID: 9650324].
57. Nikolaidis N, Kountouras J, Giouleme O, Tzarou V, Chatzizisi O, Patsiaoura K, Papageorgiou A, Leontsini M, Eugenidis N, Zamboulis C. Colchicine treatment of liver fibrosis. Hepatogastroenterology 2006; 53: 281-285 [PMID: 16608040].
58. Lang Q, Liu Q, Xu N, Qian KL, Qi JH, Sun YC, Xiao L, Shi XF. The antifibrotic effects of TGF-β1 siRNA on hepatic fibrosis in rats. Biochem Biophys Res Commun 2011; 409: 448-453 [PMID: 21600192 DOI: 10.1016/j.bbrc.2011.05.023].
59. Wright MC, Issa R, Smart DE, Trim N, Murray GI, Primrose JN, Arthur MJ, Iredale JP, Mann DA. Gliotoxin stimulates the apoptosis of human and rat hepatic stellate cells and enhances the resolution of liver fibrosis in rats. Gastroenterology 2001; 121: 685-698 [PMID: 11522753 DOI: 10.1053/gast.2001.27188].
60. Oakley F, Meso M, Iredale JP, Green K, Marek CJ, Zhou X, May MJ, Millward-Sadler H, Wright MC, Mann DA. Inhibition of inhibitor of kappa B kinases stimulates hepatic stellate cell apoptosis and accelerated recovery from rat liver fibrosis. Gastroenterology 2005; 128: 108-120 [PMID: 15633128 DOI: 10.1053/j.gastro.2004.10.003].
61. Salgado S, Garcia J, Vera J, Siller F, Bueno M, Miranda A, Segura A, Grijalva G, Segura J, Orozco H, Hernandez-Pando R, Fafutis M, Aguilar LK, Aguilar-Cordova E, Armendariz- Borunda J. Liver cirrhosis is reverted by urokinase-type plasminogen activator gene therapy. Mol Ther 2000; 2: 545-551 [PMID: 11124055 DOI: 10.1006/mthe.2000.0210].
62. Sugino H, Kumagai N, Watanabe S, Toda K, Takeuchi O, Tsunematsu S, Morinaga S, Tsuchimoto K. Polaprezinc attenuates liver fibrosis in a mouse model of non-alcoholic steatohepatitis. J Gastroenterol Hepatol 2008; 23: 1909-1916 [PMID: 18422963 DOI: 10.1111/j.1440-1746.2008.05393.x].
63. Zhang LJ, Zheng WD, Chen YX, Huang YH, Chen ZX, Zhang SJ, Shi MN, Wang XZ. Antifibrotic effects of interleukin-10 on experimental hepatic fibrosis. Hepatogastroenterology 2007; 54: 2092-2098 [PMID: 18251166].
64. Nelson DR, Tu Z, Soldevila-Pico C, Abdelmalek M, Zhu H, Xu YL, Cabrera R, Liu C, Davis GL. Long-term interleukin 10 therapy in chronic hepatitis C patients has a proviral and anti-inflammatory effect. Hepatology 2003; 38: 859-868 [PMID: 14512873 DOI: 10.1053/jhep.2003.50427].
65. Koca SS, Bahcecioglu IH, Poyrazoglu OK, Ozercan IH, Sahin K, Ustundag B. The treatment with antibody of TNFalpha reduces the inflammation, necrosis and fibrosis in the non-alcoholic steatohepatitis induced by methionine- And choline-deficient diet. Inflammation 2008; 31: 91-98 [PMID: 18066656 DOI: 10.1007/s10753-007-9053-z].
66. Spahr L, Rubbia-Brandt L, Frossard JL, Giostra E, Rougemont AL, Pugin J, Fischer M, Egger H, Hadengue A. Combination of steroids with infliximab or placebo in severe alcoholic hepatitis: a randomized controlled pilot study. J Hepatol 2002; 37: 448-455 [PMID: 12217597 DOI: 10.1016/S0168-8278(02)00230-1].
67. Nava-Ocampo AA, Suster S, Muriel P. Effect of colchiceine and ursodeoxycholic acid on hepatocyte and erythrocyte membranes and liver histology in experimentally induced carbon tetrachloride cirrhosis in rats. Eur J Clin Invest 1997; 27: 77-84 [PMID: 9041381 DOI: 10.1046/j.1365-2362.1997.910615.x].
68. Poupon RE, Lindor KD, Parés A, Chazouillères O, Poupon R, Heathcote EJ. Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis. J Hepatol 2003; 39: 12-16 [PMID: 12821038 DOI: 10.1016/S0168-8278(03)00192-2].
69. Barry-Hamilton V, Spangler R, Marshall D, McCauley S, Rodriguez HM, Oyasu M, Mikels A, Vaysberg M, Ghermazien H, Wai C, Garcia CA, Velayo AC, Jorgensen B, Biermann D, Tsai D, Green J, Zaffryar-Eilot S, Holzer A, Ogg S, Thai D, Neufeld G, Van Vlasselaer P, Smith V. Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment. Nat Med 2010; 16: 1009-1017 [PMID: 20818376 DOI: 10.1038/nm.2208].
70. Cadranel JF, Rufat P, Degos F. Practices of liver biopsy in France: results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF). Hepatology 2000; 32: 477-481 [PMID: 10960438 DOI: 10.1053/jhep.2000.16602].
71. Regev A, Berho M, Jeffers LJ, Milikowski C, Molina EG, Pyrsopoulos NT, Feng ZZ, Reddy KR, Schiff ER. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002; 97: 2614-2618 [PMID: 12385448 DOI: 10.1111/j.1572-0241.2002.06038.x].
72. Sandrin L, Fourquet B, Hasquenoph JM, Yon S, Fournier C, Mal F, Christidis C, Ziol M, Poulet B, Kazemi F, Beaugrand M, Palau R. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol 2003; 29: 1705-1713 [PMID: 14698338 DOI: 10.1016/j.ultr asmedbio.2003.07.001].
73. Kelly DA. Current issues in pediatric transplantation. Pediatr Transplant 2006; 10: 712-720 [PMID: 16911496 DOI: 10.1111/j.1399-3046.2006.00567.x].
74. Forbes SJ. Stem cell therapy for chronic liver disease- choosing the right tools for the job. Gut 2008; 57: 153-155 [PMID: 18192451 DOI: 10.1136/gut.2007.134247].
75. Francoz C, Belghiti J, Durand F. Indications of liver transplantation in patients with complications of cirrhosis. Best Pract Res Clin Gastroenterol 2007; 21: 175-190 [PMID: 17223504 DOI: 10.1016/j.bpg.2006.07.007].
76. Peeters PM, Sieders E, Vd Heuvel M, Bijleveld CM, de Jong KP, TenVergert EM, Slooff MJ, Gouw AS. Predictive factors for portal fibrosis in pediatric liver transplant recipients. Transplantation 2000; 70: 1581-1587 [PMID: 11152219 DOI: 10.1097/00007890-200012150-00008].
77. Scheenstra R, Peeters PM, Verkade HJ, Gouw AS. Graft fibrosis after pediatric liver transplantation: ten years of follow-up. Hepatology 2009; 49: 880-886 [PMID: 19101912 DOI: 10.1002/hep.22686].
78. Sokal EM, Smets F, Bourgois A, Van Maldergem L, Buts JP, Reding R, Bernard Otte J, Evrard V, Latinne D, Vincent MF, Moser A, Soriano HE. Hepatocyte transplantation in a 4-yearold girl with peroxisomal biogenesis disease: technique, safety, and metabolic follow-up. Transplantation 2003; 76: 735-738 [PMID: 12973120 DOI: 10.1097/01.TP.0000077420.81365.53].
79. Stéphenne X, Najimi M, Sibille C, Nassogne MC, Smets F, Sokal EM. Sustained engraftment and tissue enzyme activity after liver cell transplantation for argininosuccinate lyase deficiency. Gastroenterology 2006; 130: 1317-1323 [PMID: 16618422 DOI: 10.1053/j.gastro.2006.01.008].
80. Stéphenne X, Najimi M, Smets F, Reding R, de Ville de Goyet J, Sokal EM. Cryopreserved liver cell transplantation controls ornithine transcarbamylase deficient patient while awaiting liver transplantation. Am J Transplant 2005; 5: 2058-2061 [PMID: 15996260 DOI: 10.1111/j.1600-6143.2005.00935.x].
81. De Vree JM, Ottenhoff R, Bosma PJ, Smith AJ, Aten J, Oude Elferink RP. Correction of liver disease by hepatocyte transplantation in a mouse model of progressive familial intrahepatic cholestasis. Gastroenterology 2000; 119: 1720-1730 [PMID: 11113093 DOI: 10.1053/gast.2000.20222].
82. Smets F, Najimi M, Sokal EM. Cell transplantation in the treatment of liver diseases. Pediatr Transplant 2008; 12: 6-13 [PMID: 18186884 DOI: 10.1111/j.1399-3046.2007.00788.x].
83. Stéphenne X, Najimi M, Ngoc DK, Smets F, Hue L, Guigas B, Sokal EM. Cryopreservation of human hepatocytes alters the mitochondrial respiratory chain complex 1. Cell Transplant 2007; 16: 409-419 [PMID: 17658131 DOI: 10.3727/000000007783464821].
84. Yamamoto H, Quinn G, Asari A, Yamanokuchi H, Teratani T, Terada M, Ochiya T. Differentiation of embryonic stem cells into hepatocytes: biological functions and therapeutic application. Hepatology 2003; 37: 983-993 [PMID: 12717379 DOI: 10.1053/jhep.2003.50202].
85. Moriya K, Yoshikawa M, Saito K, Ouji Y, Nishiofuku M, Hayashi N, Ishizaka S, Fukui H. Embryonic stem cells develop into hepatocytes after intrasplenic transplantation in CCl4-treated mice. World J Gastroenterol 2007; 13: 866-873 [PMID: 17352015 DOI: 10.3748/wjg.v13.i6.866].
86. Moriya K, Yoshikawa M, Ouji Y, Saito K, Nishiofuku M, Matsuda R, Ishizaka S, Fukui H. Embryonic stem cells reduce liver fibrosis in CCl4-treated mice. Int J Exp Pathol 2008; 89: 401-409 [PMID: 19134049 DOI: 10.1111/j.1365-2613.2008.00607. x].
87. Cai J, Zhao Y, Liu Y, Ye F, Song Z, Qin H, Meng S, Chen Y, Zhou R, Song X, Guo Y, Ding M, Deng H. Directed differentiation of human embryonic stem cells into functional hepatic cells. Hepatology 2007; 45: 1229-1239 [PMID: 17464996 DOI: 10.1002/hep.21582].
88. Ishii T, Yasuchika K, Machimoto T, Kamo N, Komori J, Konishi S, Suemori H, Nakatsuji N, Saito M, Kohno K, Uemoto S, Ikai I. Transplantation of embryonic stem cellderived endodermal cells into mice with induced lethal liver damage. Stem Cells 2007; 25: 3252-3260 [PMID: 17885077 DOI: 10.1634/stemcells.2007-0199].
89. Choi D, Oh HJ, Chang UJ, Koo SK, Jiang JX, Hwang SY, Lee JD, Yeoh GC, Shin HS, Lee JS, Oh B. In vivo differentiation of mouse embryonic stem cells into hepatocytes. Cell Transplant 2002; 11: 359-368 [PMID: 12162376].
90. Gilchrist ES, Plevris JN. Bone marrow-derived stem cells in liver repair: 10 years down the line. Liver Transpl 2010; 16: 118-129 [PMID: 20104479 DOI: 10.1002/lt.21965].
91. Song Z, Cai J, Liu Y, Zhao D, Yong J, Duo S, Song X, Guo Y, Zhao Y, Qin H, Yin X, Wu C, Che J, Lu S, Ding M, Deng H. Efficient generation of hepatocyte-like cells from human induced pluripotent stem cells. Cell Res 2009; 19: 1233-1242 [PMID: 19736565 DOI: 10.1038/cr.2009.107].
92. Liu H, Kim Y, Sharkis S, Marchionni L, Jang YY. In vivo liver regeneration potential of human induced pluripotent stem cells from diverse origins. Sci Transl Med 2011; 3: 82ra39 [PMID: 21562231 DOI: 10.1126/scitranslmed.3002376].
93. Chun YS, Chaudhari P, Jang YY. Applications of patientspecific induced pluripotent stem cells; focused on disease modeling, drug screening and therapeutic potentials for liver disease. Int J Biol Sci 2010; 6: 796-805 [PMID: 21179587 DOI: 10.7150/ijbs.6.796].
94. Ren G, Chen X, Dong F, Li W, Ren X, Zhang Y, Shi Y. Concise review: mesenchymal stem cells and translational medicine: emerging issues. Stem Cells Transl Med 2012; 1: 51-58 [PMID: 23197640 DOI: 10.5966/sctm.2011-0019].
95. Berardis S, Lombard C, Evraerts J, El Taghdouini A, Rosseels V, Sancho-Bru P, Lozano JJ, van Grunsven L, Sokal E, Najimi M. Gene expression profiling and secretome analysis differentiate adult-derived human liver stem/progenitor cells and human hepatic stellate cells. PLoS One 2014; 9: e86137 [PMID: 24516514 DOI: 10.1371/journal. pone.0086137].
96. Prockop DJ, Brenner M, Fibbe WE, Horwitz E, Le Blanc K, Phinney DG, Simmons PJ, Sensebe L, Keating A. Defining the risks of mesenchymal stromal cell therapy. Cytotherapy 2010; 12: 576-578 [PMID: 20735162 DOI: 10.3109/14653249.2 010.507330].
97. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop Dj, Horwitz E. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006; 8: 315-317 [PMID: 16923606 DOI: 10.1080/14653240600855905].
98. Barry FP, Murphy JM. Mesenchymal stem cells: clinical applications and biological characterization. Int J Biochem Cell Biol 2004; 36: 568-584 [PMID: 15010324 DOI: 10.1016/j.biocel.2003.11.001].
99. Barry F, Boynton RE, Liu B, Murphy JM. Chondrogenic differentiation of mesenchymal stem cells from bone marrow: differentiation-dependent gene expression of matrix components. Exp Cell Res 2001; 268: 189-200 [PMID: 11478845 DOI: 10.1006/excr.2001.5278].
100. Johnstone B, Hering TM, Caplan AI, Goldberg VM, Yoo JU. In vitro chondrogenesis of bone marrow-derived mesenchymal progenitor cells. Exp Cell Res 1998; 238: 265-272 [PMID: 9457080 DOI: 10.1006/excr.1997.3858].
101. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S, Marshak DR. Multilineage potential of adult human mesenchymal stem cells. Science 1999; 284: 143-147 [PMID: 10102814 DOI: 10.1126/science.284.5411.143].
102. Sanchez-Ramos J, Song S, Cardozo-Pelaez F, Hazzi C, Stedeford T, Willing A, Freeman TB, Saporta S, Janssen W, Patel N, Cooper DR, Sanberg PR. Adult bone marrow stromal cells differentiate into neural cells in vitro. Exp Neurol 2000; 164: 247-256 [PMID: 10915564 DOI: 10.1006/exnr.2000.7389].
103. Jiang Y, Jahagirdar BN, Reinhardt RL, Schwartz RE, Keene CD, Ortiz-Gonzalez XR, Reyes M, Lenvik T, Lund T, Blackstad M, Du J, Aldrich S, Lisberg A, Low WC, Largaespada DA, Verfaillie CM. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 2002; 418: 41-49 [PMID: 12077603 DOI: 10.1038/nature00870].
104. Schwartz RE, Reyes M, Koodie L, Jiang Y, Blackstad M, Lund T, Lenvik T, Johnson S, Hu WS, Verfaillie CM. Multipotent adult progenitor cells from bone marrow differentiate into functional hepatocyte-like cells. J Clin Invest 2002; 109: 1291-1302 [PMID: 12021244 DOI: 10.1172/JCI0215182].
105. Taléns-Visconti R, Bonora A, Jover R, Mirabet V, Carbonell F, Castell JV, Gómez-Lechón MJ. Hepatogenic differentiation of human mesenchymal stem cells from adipose tissue in comparison with bone marrow mesenchymal stem cells. World J Gastroenterol 2006; 12: 5834-5845 [PMID: 17007050].
106. Sato Y, Araki H, Kato J, Nakamura K, Kawano Y, Kobune M, Sato T, Miyanishi K, Takayama T, Takahashi M, Takimoto R, Iyama S, Matsunaga T, Ohtani S, Matsuura A, Hamada H, Niitsu Y. Human mesenchymal stem cells xenografted directly to rat liver are differentiated into human hepatocytes without fusion. Blood 2005; 106: 756-763 [PMID: 15817682 DOI: 10.1182/blood-2005-02-0572].
107. Shu SN, Wei L, Wang JH, Zhan YT, Chen HS, Wang Y. Hepatic differentiation capability of rat bone marrow-derived mesenchymal stem cells and hematopoietic stem cells. World J Gastroenterol 2004; 10: 2818-2822 [PMID: 15334677].
108. Theise ND, Badve S, Saxena R, Henegariu O, Sell S, Crawford JM, Krause DS. Derivation of hepatocytes from bone marrow cells in mice after radiation-induced myeloablation. Hepatology 2000; 31: 235-240 [PMID: 10613752 DOI: 10.1002/hep.510310135].
109. Chamberlain J, Yamagami T, Colletti E, Theise ND, Desai J, Frias A, Pixley J, Zanjani ED, Porada CD, Almeida- Porada G. Efficient generation of human hepatocytes by the intrahepatic delivery of clonal human mesenchymal stem cells in fetal sheep. Hepatology 2007; 46: 1935-1945 [PMID: 17705296 DOI: 10.1002/hep.21899].
110. Alison MR, Poulsom R, Jeffery R, Dhillon AP, Quaglia A, Jacob J, Novelli M, Prentice G, Williamson J, Wright NA. Hepatocytes from non-hepatic adult stem cells. Nature 2000; 406: 257 [PMID: 10917519 DOI: 10.1038/35018642].
111. Najimi M, Khuu DN, Lysy PA, Jazouli N, Abarca J, Sempoux C, Sokal EM. Adult-derived human liver mesenchymal-like cells as a potential progenitor reservoir of hepatocytes? Cell Transplant 2007; 16: 717-728 [PMID: 18019361 DOI: 10.3727/0 00000007783465154].
112. Khuu DN, Scheers I, Ehnert S, Jazouli N, Nyabi O, Buc- Calderon P, Meulemans A, Nussler A, Sokal E, Najimi M. In vitro differentiated adult human liver progenitor cells display mature hepatic metabolic functions: a potential tool for in vitro pharmacotoxicological testing. Cell Transplant 2011; 20: 287-302 [PMID: 20719066 DOI: 10.3727/096368910 X516655].
113. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005; 105: 1815-1822 [PMID: 15494428 DOI: 10.1182/blood-2004-04-1559].
114. Puglisi MA, Tesori V, Lattanzi W, Piscaglia AC, Gasbarrini GB, D'Ugo DM, Gasbarrini A. Therapeutic implications of mesenchymal stem cells in liver injury. J Biomed Biotechnol 2011; 2011: 860578 [PMID: 22228987 DOI: 10.1155/2011/860578].
115. Corcione A, Benvenuto F, Ferretti E, Giunti D, Cappiello V, Cazzanti F, Risso M, Gualandi F, Mancardi GL, Pistoia V, Uccelli A. Human mesenchymal stem cells modulate B-cell functions. Blood 2006; 107: 367-372 [PMID: 16141348 DOI: 10.1182/blood-2005-07-2657].
116. Jiang XX, Zhang Y, Liu B, Zhang SX, Wu Y, Yu XD, Mao N. Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood 2005; 105: 4120-4126 [PMID: 15692068 DOI: 10.1182/blood-2004-02-0586].
117. Zhang W, Ge W, Li C, You S, Liao L, Han Q, Deng W, Zhao RC. Effects of mesenchymal stem cells on differentiation, maturation, and function of human monocyte-derived dendritic cells. Stem Cells Dev 2004; 13: 263-271 [PMID: 15186722 DOI: 10.1089/154732804323099190].
118. Spaggiari GM, Abdelrazik H, Becchetti F, Moretta L. MSCs inhibit monocyte-derived DC maturation and function by selectively interfering with the generation of immature DCs: central role of MSC-derived prostaglandin E2. Blood 2009; 113: 6576-6583 [PMID: 19398717 DOI: 10.1182/blood-2009-02-203943].
119. Spaggiari GM, Capobianco A, Abdelrazik H, Becchetti F, Mingari MC, Moretta L. Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2, 3-dioxygenase and prostaglandin E2. Blood 2008; 111: 1327-1333 [PMID: 17951526 DOI: 10.1182/blood-2007-02-074997].
120. Basciano L, Nemos C, Foliguet B, de Isla N, de Carvalho M, Tran N, Dalloul A. Long term culture of mesenchymal stem cells in hypoxia promotes a genetic program maintaining their undifferentiated and multipotent status. BMC Cell Biol 2011; 12: 12 [PMID: 21450070 DOI: 10.1186/1471-2121-12-12].
121. Salem HK, Thiemermann C. Mesenchymal stromal cells: current understanding and clinical status. Stem Cells 2010; 28: 585-596 [PMID: 19967788 DOI: 10.1002/stem.269].
122. Kansas GS. Selectins and their ligands: current concepts and controversies. Blood 1996; 88: 3259-3287 [PMID: 8896391].
123. Rüster B, Göttig S, Ludwig RJ, Bistrian R, Müller S, Seifried E, Gille J, Henschler R. Mesenchymal stem cells display coordinated rolling and adhesion behavior on endothelial cells. Blood 2006; 108: 3938-3944 [PMID: 16896152 DOI: 10.1182/blood-2006-05-025098].
124. van Poll D, Parekkadan B, Cho CH, Berthiaume F, Nahmias Y, Tilles AW, Yarmush ML. Mesenchymal stem cellderived molecules directly modulate hepatocellular death and regeneration in vitro and in vivo. Hepatology 2008; 47: 1634-1643 [PMID: 18395843 DOI: 10.1002/hep.22236].
125. Zhang S, Chen L, Liu T, Zhang B, Xiang D, Wang Z, Wang Y. Human umbilical cord matrix stem cells efficiently rescue acute liver failure through paracrine effects rather than hepatic differentiation. Tissue Eng Part A 2012; 18: 1352-1364 [PMID: 22519429 DOI: 10.1089/ten.tea.2011.0516].
126. Li T, Yan Y, Wang B, Qian H, Zhang X, Shen L, Wang M, Zhou Y, Zhu W, Li W, Xu W. Exosomes derived from human umbilical cord mesenchymal stem cells alleviate liver fibrosis. Stem Cells Dev 2013; 22: 845-854 [PMID: 23002959 DOI: 10.1089/scd.2012.0395].
127. Jung KH, Shin HP, Lee S, Lim YJ, Hwang SH, Han H, Park HK, Chung JH, Yim SV. Effect of human umbilical cord blood-derived mesenchymal stem cells in a cirrhotic rat model. Liver Int 2009; 29: 898-909 [PMID: 19422480 DOI: 10.1111/j.1478-3231.2009.02031.x].
128. Wang Y, Lian F, Li J, Fan W, Xu H, Yang X, Liang L, Chen W, Yang J. Adipose derived mesenchymal stem cells transplantation via portal vein improves microcirculation and ameliorates liver fibrosis induced by CCl4 in rats. J Transl Med 2012; 10: 133 [PMID: 22735033 DOI: 10.1186/147 9-5876-10-133].
129. Nasir GA, Mohsin S, Khan M, Shams S, Ali G, Khan SN, Riazuddin S. Mesenchymal stem cells and Interleukin-6 attenuate liver fibrosis in mice. J Transl Med 2013; 11: 78 [PMID: 23531302 DOI: 10.1186/1479-5876-11-78].
130. Li Q, Zhou X, Shi Y, Li J, Zheng L, Cui L, Zhang J, Wang L, Han Z, Han Y, Fan D. In vivo tracking and comparison of the therapeutic effects of MSCs and HSCs for liver injury. PLoS One 2013; 8: e62363 [PMID: 23638052 DOI: 10.1371/journal.pone.0062363].
131. Chang YJ, Liu JW, Lin PC, Sun LY, Peng CW, Luo GH, Chen TM, Lee RP, Lin SZ, Harn HJ, Chiou TW. Mesenchymal stem cells facilitate recovery from chemically induced liver damage and decrease liver fibrosis. Life Sci 2009; 85: 517-525 [PMID: 19686763 DOI: 10.1016/j.lfs.2009.08.003].
132. Rabani V, Shahsavani M, Gharavi M, Piryaei A, Azhdari Z, Baharvand H. Mesenchymal stem cell infusion therapy in a carbon tetrachloride-induced liver fibrosis model affects matrix metalloproteinase expression. Cell Biol Int 2010; 34: 601-605 [PMID: 20178458 DOI: 10.1042/CBI20090386].
133. Zhao DC, Lei JX, Chen R, Yu WH, Zhang XM, Li SN, Xiang P. Bone marrow-derived mesenchymal stem cells protect against experimental liver fibrosis in rats. World J Gastroenterol 2005; 11: 3431-3440 [PMID: 15948250].
134. Abdel Aziz MT, Atta HM, Mahfouz S, Fouad HH, Roshdy NK, Ahmed HH, Rashed LA, Sabry D, Hassouna AA, Hasan NM. Therapeutic potential of bone marrow-derived mesenchymal stem cells on experimental liver fibrosis. Clin Biochem 2007; 40: 893-899 [PMID: 17543295 DOI: 10.1016/j.clinbiochem.2007.04.017].
135. Tanimoto H, Terai S, Taro T, Murata Y, Fujisawa K, Yamamoto N, Sakaida I. Improvement of liver fibrosis by infusion of cultured cells derived from human bone marrow. Cell Tissue Res 2013; 354: 717-728 [PMID: 24104560 DOI: 10.1007/s00441-013-1727-2].
136. Starkel P, Leclercq IA. Animal models for the study of hepatic fibrosis. Best Pract Res Clin Gastroenterol 2011; 25: 319-333 [PMID: 21497748 DOI: 10.1016/j.bpg.2011.02.004].
137. Ortiz LA, Gambelli F, McBride C, Gaupp D, Baddoo M, Kaminski N, Phinney DG. Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects. Proc Natl Acad Sci USA 2003; 100: 8407-8411 [PMID: 12815096 DOI: 10.1073/pnas.1432929100].
138. Schubert T, Xhema D, Vériter S, Schubert M, Behets C, Delloye C, Gianello P, Dufrane D. The enhanced performance of bone allografts using osteogenic-differentiated adiposederived mesenchymal stem cells. Biomaterials 2011; 32: 8880-8891 [PMID: 21872925 DOI: 10.1016/j.biomaterials.2011. 08.009].
139. Parekkadan B, van Poll D, Megeed Z, Kobayashi N, Tilles AW, Berthiaume F, Yarmush ML. Immunomodulation of activated hepatic stellate cells by mesenchymal stem cells. Biochem Biophys Res Commun 2007; 363: 247-252 [PMID: 17869217 DOI: 10.1016/j.bbrc.2007.05.150].
140. Wang J, Bian C, Liao L, Zhu Y, Li J, Zeng L, Zhao RC. Inhibition of hepatic stellate cells proliferation by mesenchymal stem cells and the possible mechanisms. Hepatol Res 2009; 39: 1219-1228 [PMID: 19788697 DOI: 10.1111/j.1872-034X.2009.00564.x].
141. Lin N, Hu K, Chen S, Xie S, Tang Z, Lin J, Xu R. Nerve growth factor-mediated paracrine regulation of hepatic stellate cells by multipotent mesenchymal stromal cells. Life Sci 2009; 85: 291-295 [PMID: 19559033 DOI: 10.1016/j.lfs.2009.06.007].
142. Chen S, Xu L, Lin N, Pan W, Hu K, Xu R. Activation of Notch1 signaling by marrow-derived mesenchymal stem cells through cell-cell contact inhibits proliferation of hepatic stellate cells. Life Sci 2011; 89: 975-981 [PMID: 22056375 DOI: 10.1016/j.lfs.2011.10.012].
143. Wang PP, Xie DY, Liang XJ, Peng L, Zhang GL, Ye YN, Xie C, Gao ZL. HGF and direct mesenchymal stem cells contact synergize to inhibit hepatic stellate cells activation through TLR4/NF-kB pathway. PLoS One 2012; 7: e43408 [PMID: 22927965 DOI: 10.1371/journal.pone.0043408].
144. Zhang Z, Lin H, Shi M, Xu R, Fu J, Lv J, Chen L, Lv S, Li Y, Yu S, Geng H, Jin L, Lau GK, Wang FS. Human umbilical cord mesenchymal stem cells improve liver function and ascites in decompensated liver cirrhosis patients. J Gastroenterol Hepatol 2012; 27 Suppl 2: 112-120 [PMID: 22320928 DOI: 10.1111/j.1440-1746.2011.07024.x].
145. Shi M, Zhang Z, Xu R, Lin H, Fu J, Zou Z, Zhang A, Shi J, Chen L, Lv S, He W, Geng H, Jin L, Liu Z, Wang FS. Human mesenchymal stem cell transfusion is safe and improves liver function in acute-on-chronic liver failure patients. Stem Cells Transl Med 2012; 1: 725-731 [PMID: 23197664 DOI: 10.5966/sctm.2012-0034].
146. Wang L, Li J, Liu H, Li Y, Fu J, Sun Y, Xu R, Lin H, Wang S, Lv S, Chen L, Zou Z, Li B, Shi M, Zhang Z, Wang FS. Pilot study of umbilical cord-derived mesenchymal stem cell transfusion in patients with primary biliary cirrhosis. J Gastroenterol Hepatol 2013; 28 Suppl 1: 85-92 [PMID: 23855301 DOI: 10.1111/jgh.12029].
147. Mohamadnejad M, Alimoghaddam K, Mohyeddin-Bonab M, Bagheri M, Bashtar M, Ghanaati H, Baharvand H, Ghavamzadeh A, Malekzadeh R. Phase 1 trial of autologous bone marrow mesenchymal stem cell transplantation in patients with decompensated liver cirrhosis. Arch Iran Med 2007; 10: 459-466 [PMID: 17903050].
148. Kharaziha P, Hellström PM, Noorinayer B, Farzaneh F, Aghajani K, Jafari F, Telkabadi M, Atashi A, Honardoost M, Zali MR, Soleimani M. Improvement of liver function in liver cirrhosis patients after autologous mesenchymal stem cell injection: a phase I-II clinical trial. Eur J Gastroenterol Hepatol 2009; 21: 1199-1205 [PMID: 19455046 DOI: 10.1097/MEG.0b013e32832a1f6c].
149. Peng L, Xie DY, Lin BL, Liu J, Zhu HP, Xie C, Zheng YB, Gao ZL. Autologous bone marrow mesenchymal stem cell transplantation in liver failure patients caused by hepatitis B: short-term and long-term outcomes. Hepatology 2011; 54: 820-828 [PMID: 21608000 DOI: 10.1002/hep.24434].
150. El-Ansary M, Abdel-Aziz I, Mogawer S, Abdel-Hamid S, Hammam O, Teaema S, Wahdan M. Phase II trial: undifferentiated versus differentiated autologous mesenchymal stem cells transplantation in Egyptian patients with HCV induced liver cirrhosis. Stem Cell Rev 2012; 8: 972-981 [PMID: 21989829 DOI: 10.1007/s12015-011-9322-y].
151. Amin MA, Sabry D, Rashed LA, Aref WM, el-Ghobary MA, Farhan MS, Fouad HA, Youssef YA. Short-term evaluation of autologous transplantation of bone marrow-derived mesenchymal stem cells in patients with cirrhosis: Egyptian study. Clin Transplant 2013; 27: 607-612 [PMID: 23923970 DOI: 10.1111/ctr.12179].
152. Jang YO, Kim YJ, Baik SK, Kim MY, Eom YW, Cho MY, Park HJ, Park SY, Kim BR, Kim JW, Soo Kim H, Kwon SO, Choi EH, Kim YM. Histological improvement following administration of autologous bone marrow-derived mesenchymal stem cells for alcoholic cirrhosis: a pilot study. Liver Int 2014; 34: 33-41 [PMID: 23782511].
153. Kamath PS, Kim WR. The model for end-stage liver disease (MELD). Hepatology 2007; 45: 797-805 [PMID: 17326206 DOI: 10.1002/hep.21563].
154. Zhu W, Xu W, Jiang R, Qian H, Chen M, Hu J, Cao W, Han C, Chen Y. Mesenchymal stem cells derived from bone marrow favor tumor cell growth in vivo. Exp Mol Pathol 2006; 80: 267-274 [PMID: 16214129 DOI: 10.1016/j.yexmp.2005.07.004].
155. Djouad F, Plence P, Bony C, Tropel P, Apparailly F, Sany J, Noël D, Jorgensen C. Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood 2003; 102: 3837-3844 [PMID: 12881305 DOI: 10.1182/blood-2003-04-1193].
156. Yu JM, Jun ES, Bae YC, Jung JS. Mesenchymal stem cells derived from human adipose tissues favor tumor cell growth in vivo. Stem Cells Dev 2008; 17: 463-473 [PMID: 18522494 DOI: 10.1089/scd.2007.0181].
157. Khakoo AY, Pati S, Anderson SA, Reid W, Elshal MF, Rovira II, Nguyen AT, Malide D, Combs CA, Hall G, Zhang J, Raffeld M, Rogers TB, Stetler-Stevenson W, Frank JA, Reitz M, Finkel T. Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma. J Exp Med 2006; 203: 1235-1247 [PMID: 16636132 DOI: 10.1084/jem.20051921].
158. Qiao L, Xu Z, Zhao T, Zhao Z, Shi M, Zhao RC, Ye L, Zhang X. Suppression of tumorigenesis by human mesenchymal stem cells in a hepatoma model. Cell Res 2008; 18: 500-507 [PMID: 18364678 DOI: 10.1038/cr.2008.40].
159. Lu YR, Yuan Y, Wang XJ, Wei LL, Chen YN, Cong C, Li SF, Long D, Tan WD, Mao YQ, Zhang J, Li YP, Cheng JQ. The growth inhibitory effect of mesenchymal stem cells on tumor cells in vitro and in vivo. Cancer Biol Ther 2008; 7: 245-251 [PMID: 18059192].
160. Gao P, Ding Q, Wu Z, Jiang H, Fang Z. Therapeutic potential of human mesenchymal stem cells producing IL-12 in a mouse xenograft model of renal cell carcinoma. Cancer Lett 2010; 290: 157-166 [PMID: 19786319 DOI: 10.1016/j.canlet.2009.08.031].
161. Abdelaziz MT, El-Asmar MF, Atta HM, Mahfouz S, Fouad HH, Roshdy NK, Rashed LA, Sabry D, Hassouna AA, Taha FM. Efficacy of mesenchymal stem cells in suppression of hepatocarcinorigenesis in rats: possible role of Wnt signaling. J Exp Clin Cancer Res 2011; 30: 49 [PMID: 21545718].